Italian Medicines Agency publishes concept paper on biosimilars

Home/Guidelines | Posted 21/09/2012 post-comment0 Post your comment

The Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) announced on 1 August 2012 the release of a concept paper on biosimilars.

picture43

The purpose of the concept paper on biosimilar drugs is to ensure and promote the use of biosimilars in Italy by providing health professionals and citizens authoritative, clear, transparent, objective and validated information. Subjects covered by the concept paper include:

  • Definition and criteria for the characterisation and naming of biological medicines and biosimilars
  • Regulatory requirements in force in the EU with respect to biosimilars
  • Safety of biosimilars
  • Extrapolation of therapeutic indications for biosimilars
  • Role of biosimilars in the Italian healthcare system
  • Biosimilars as an alternative to brand-name products: the question of substitution

AIFA sees biosimilars as essential for the development of a competitive market and for the sustainability of the healthcare system. At the same time AIFA sees the importance of maintaining guarantees of safety and quality for patients and the role that biosimilars have in providing patients with timely access to medicines, even in the context of public spending cuts.

Biological medicinal products and biosimilars play a vital role in the treatment of many diseases, for this reason, AIFA considers it essential to provide a document whose purpose is to define the conditions in the pharmaceutical field to ensure proper use and access for biosimilar products.

The contents of the concept paper do not yet reflect the official position of AIFA in the field of biosimilars, but constitute a preliminary position on which to explore the different viewpoints of stakeholders through a public consultation.

The concept paper is available on the AIFA website for public consultation, by consumers, pharmaceutical companies, scientific societies, and others until 31 October 2012. A form for comments is available from www.agenziafarmaco.gov.it/sites/default/files/modulo_public_consultation_biosimilari.doc

Related articles

Italian physicians’ negative attitude to generics

Italy to scrap tender system to boost generic volumes

Permission granted to reproduce for personal and educational use only. All other reproduction, copy, retransmission or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: AIFA

comment icon Comments (0)
Post your comment
Related content
FDA updates generics guidance due to COVID-19 pandemic
34 AA010660
Home/Guidelines Posted 01/10/2021
WHO guidelines on pharmaceutical pricing policies
Pay for Delay DrugsMoneyGeneric V13F21
Home/Guidelines Posted 24/09/2021
Mexico introduces new decree on health regulation
Regulation-V13H16
Home/Guidelines Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010